Pro Share Advisors LLC Cyma Bay Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $86,098 - $166,811	6,817 Added 35.58%	25,976 $613,000
Q3 2023 Nov 13, 2023	BUY	$10.86 - $17.62 $1,009 - $1,638	93 Added 0.49%	19,159 $285,000
Q2 2023 Aug 10, 2023	BUY	$7.47 - $10.95 $142,423 - $208,772	19,066 New	19,066 $208,000
Q2 2022 Aug 01, 2022	SELL	$1.72 - $3.39 $42,520 - $83,804	-24,721 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$2.77 - $3.64 $6,492 - $8,532	-2,344 Reduced 8.66%	24,721 $76,000
Q4 2021 Feb 08, 2022	BUY	$3.23 - $4.6 $11,120 - $15,837	3,443 Added 14.58%	27,065 $92,000
Q3 2021 Nov 12, 2021	SELL	$3.47 - $4.42 $23,443 - $29,861	-6,756 Reduced 22.24%	23,622 $86,000
Q2 2021 Aug 13, 2021	BUY	$3.94 - $4.92 $9,215 - $11,507	2,339 Added 8.34%	30,378 $132,000
Q1 2021 May 14, 2021	BUY	$4.23 - $6.55 $8,705 - $13,479	2,058 Added 7.92%	28,039 $127,000
Q4 2020 Feb 09, 2021	BUY	$5.73 - $9.03 $36,608 - $57,692	6,389 Added 32.61%	25,981 $149,000
Q3 2020 Nov 13, 2020	SELL	$3.32 - $7.24 $2,745 - $5,987	-827 Reduced 4.05%	19,592 $142,000
Q2 2020 Aug 03, 2020	BUY	$1.41 - $4.25 $9,776 - $29,469	6,934 Added 51.42%	20,419 $71,000
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $13,387 - $21,634	-10,710 Reduced 44.27%	13,485 $20,000
Q4 2019 Feb 12, 2020	SELL	$1.33 - $5.93 $2,991 - $13,336	-2,249 Reduced 8.5%	24,195 $47,000
Q3 2019 Nov 12, 2019	BUY	$5.12 - $7.21 $430 - $605	84 Added 0.32%	26,444 $135,000
Q2 2019 Aug 13, 2019	SELL	$6.05 - $13.66 $1,948 - $4,398	-322 Reduced 1.21%	26,360 $189,000
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $2,684 - $4,415	329 Added 1.25%	26,682 $354,000
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $172,348 - $309,384	26,353 New	26,353 $207,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account